Get Integrated Data for Your Specialty and Interest Aresa
 
Category Select :
Items 101 ~ 120 of 25664, Page 6 of 1284
101. Mercks KEYTRUDA (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS 10) - 11/14/2018
 MERCK
  With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients
102. AMA President Outlines Efforts to Attack Dysfunction in Health Care - 11/14/2018
 American Medical Association
103. Newest Prediabetes Awareness Campaign by Nations Medical Authorities Spreads the Word: 1 in 3 Americans Has Prediabetes, Learn Your Risk - 11/14/2018
 Centers for Disease Control and Prevention
  On World Diabetes Day 2018, the American Medical Association (AMA), the Centers for Disease Control and Prevention (CDC) and the Ad Council continue the fight against type 2 diabetes
104. Prediabetes Campaign: 1 in 3 in U.S. Has Prediabetes, Learn Your Risk - 11/14/2018
 American Medical Association
  On World Diabetes Day 2018, the AMA, the CDC and the Ad Council continue the fight against type 2 diabetes.
105. Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC - 11/14/2018
 Abbott
  ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ --?Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company''''s outstanding shares. Baker Mills'''' offer price of $57.00 per share in cash is approximately 22 percent lower than the $72.79 closing price of Abbott common shares on Nov. 9, 2018, the last closing price prior to commencement of the offer.
106. Merck Begins Rolling Submission of Licensure Application for V920 (rVSV G-ZEBOV-GP) to U.S. Food and Drug Administration - 11/13/2018
 MERCK
  V920 is the Company's Investigational Vaccine for Ebola Zaire
107. FDA warns StemGenex Biologic Laboratories LLC of illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at risk - 11/13/2018
 U.S. FOOD & DRUG ADMINISTRATION
  The U.S. Food and Drug Administration has warned StemGenex Biologic Laboratories LLC (StemGenex) of San Diego, Calif; its owner/manager Rita F. Alexander and laboratory and medical director Jenny R. Galloway, M.D. about marketing a purported stem cell product without FDA approval ...
108. AMA Adopts New Policies at 2018 Interim Meeting - 11/13/2018
 American Medical Association
  Affirming the Medical Spectrum of Gender / Protecting the Integrity of Public Health Data Collection / Opposing the Detention of Migrant Children / Increased Access to Identification Cards for the Homeless Population / Increasing Patient Access to Sexual Assault Medical Forensic Examinations and Post-Exposure Prophylaxis (PEP) for HIV in Emergency Departments
109. New AMA Policies Adopted on Final Day of 2018 Interim Meeting - 11/13/2018
 American Medical Association
  Protecting and Improving Access to Zero-dollar Preventive Care / Continued 9-1-1 Modernization and Implementation of Text-to-9-1-1 Service / Expanding Broadband and Wireless Connectivity / Sexual Assault Education and Prevention in Public Schools
110. Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System - 11/13/2018
 Medtronic
  Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease
111. Future Physicians Should Seek Training to Enhance Access to Rural Care - 11/13/2018
 American Medical Association
  The AMA encourages medical students and residents to seek training opportunities in public and population health to increase access to care in rural areas.
112. AMA Policy Aimed at Preventing Medical Student and Physician Suicide - 11/13/2018
 American Medical Association
  The AMA adopted policy during its Interim Meeting aimed at identifying patterns that could predict and ultimately prevent suicide among physicians-in-training.
113. AMA Adopts Policy to Bolster Firearm Background Checks - 11/13/2018
 American Medical Association (AMA)
  AMA calls on states to strengthen their reporting of mental health records to NICS to help prevent firearm injuries and deaths.
114. AMA Expands Anti-tobacco Policies to Further Protect Youth - 11/13/2018
 American Medical Association (AMA)
  The AMA adopted policies encouraging the FDA to prohibit the use of flavoring agents in tobacco products, including electronic nicotine delivery systems.
115. AMA Policy Supporting Survivors of LGBTQ Intimate Partner Violence - 11/13/2018
 American Medical Association
  The policy calls for physician awareness of IPV among LGBTQ patients, and funding for programs and services for survivors that do not discriminate against commu
116. AMA Advocates for Transparency in Food Labeling and Packaging - 11/13/2018
 American Medical Association (AMA)
  The AMA urges the FDA to develop front-of-package warning labels for foods that are high in added sugars based on the established recommended daily value.
117. AMA Adopts Ethical Guidance for Health Care Decisions Involving Minors - 11/12/2018
 American Medical Association
  Physicians at the AMA Interim Meeting approved a general framework to work with families to balance the childs interests with the scope of parental authority.
118. AMA Policy on In-person Importation of Prescription Drugs from Canada - 11/12/2018
 American Medical Association
  Physicians at the Interim Meeting of the AMA adopted policy supporting in-person importation of prescription drugs from licensed Canadian pharmacies.
119. AAOS on Potentially Misvalued Codes in 2019 Medicare Physician Fee Schedule - 11/12/2018
 American Academy of Orthopaedic Surgeons
120. FDA Accepts Regulatory Submission for LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - 11/12/2018
 MERCK
  Approval Would Expand Use of AstraZeneca and Mercks LYNPARZA to These Patients in the First-Line Setting Following Platinum-Based Chemotherapy / First U.S. Regulatory Submission Acceptance for a PARP Inhibitor as a First-Line Maintenance Treatment for Certain Patients with Advanced Ovarian Cancer
<<  <  [1]  [2]  [3]  [4]  [5]  [6[7]  [8]  [9]  [10]  >  >>
 


Copyright ~2018 by Medisurf. All Rights Reserved Terms of Service Privacy Email : medalls@medalls.com